OA11489A - Composition hormonale topique à effet systémique. - Google Patents

Composition hormonale topique à effet systémique. Download PDF

Info

Publication number: OA11489A
Authority: OA; OAPI
Prior art keywords: systemic; film; propylene glycol; topical; hormonal composition
Prior art date: 1998-03-23

Application number

OA1200000259A

Other languages

English (en)

French (fr)

Inventor

Michel Lanquetin

Jacques Paris

Jean-Louis Thomas

Original Assignee

Theramex

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-23

Filing date

2000-09-22

Publication date

2004-05-08

2000-09-22 Application filed by Theramex filed Critical Theramex

2004-05-08 Publication of OA11489A publication Critical patent/OA11489A/fr

Links

239000000203 mixture Substances 0.000 title claims abstract description 130
230000009885 systemic effect Effects 0.000 title claims abstract description 41
230000003054 hormonal effect Effects 0.000 title claims abstract description 36
230000000699 topical effect Effects 0.000 title claims abstract description 35
239000003795 chemical substances by application Substances 0.000 claims abstract description 41
239000002904 solvent Substances 0.000 claims abstract description 30
239000003349 gelling agent Substances 0.000 claims abstract description 21
NVUUMOOKVFONOM-GPBSYSOESA-N 19-Norprogesterone Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 NVUUMOOKVFONOM-GPBSYSOESA-N 0.000 claims abstract description 8
238000004519 manufacturing process Methods 0.000 claims abstract description 6
230000007812 deficiency Effects 0.000 claims abstract description 5
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 258
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 91
229960004190 nomegestrol acetate Drugs 0.000 claims description 69
IIVBFTNIGYRNQY-YQLZSBIMSA-N nomegestrol acetate Chemical group C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 IIVBFTNIGYRNQY-YQLZSBIMSA-N 0.000 claims description 69
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 47
239000004480 active ingredient Substances 0.000 claims description 43
229920002125 Sokalan® Polymers 0.000 claims description 29
XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 19
229940124532 absorption promoter Drugs 0.000 claims description 17
239000006185 dispersion Substances 0.000 claims description 17
229920002678 cellulose Polymers 0.000 claims description 15
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 15
239000001913 cellulose Substances 0.000 claims description 14
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 14
239000000583 progesterone congener Substances 0.000 claims description 14
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 13
229960004911 nomegestrol Drugs 0.000 claims description 11
KZUIYQJTUIACIG-YBZCJVABSA-N nomegestrol Chemical group C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 KZUIYQJTUIACIG-YBZCJVABSA-N 0.000 claims description 10
VTDOEFXTVHCAAM-UHFFFAOYSA-N 4-methylpent-3-ene-1,2,3-triol Chemical group CC(C)=C(O)C(O)CO VTDOEFXTVHCAAM-UHFFFAOYSA-N 0.000 claims description 7
150000002148 esters Chemical class 0.000 claims description 7
239000000546 pharmaceutical excipient Substances 0.000 claims description 7
229920000036 polyvinylpyrrolidone Chemical class 0.000 claims description 7
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
150000002170 ethers Chemical class 0.000 claims description 6
238000012937 correction Methods 0.000 claims description 5
125000005395 methacrylic acid group Chemical class 0.000 claims description 5
239000001267 polyvinylpyrrolidone Chemical class 0.000 claims description 5
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 claims description 3
150000001298 alcohols Chemical class 0.000 claims description 3
125000000129 anionic group Chemical group 0.000 claims description 3
229960001631 carbomer Drugs 0.000 claims description 3
229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 3
229920003145 methacrylic acid copolymer Polymers 0.000 claims description 3
PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 claims description 3
238000006467 substitution reaction Methods 0.000 claims description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
125000005456 glyceride group Chemical group 0.000 claims description 2
229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 claims description 2
229940113116 polyethylene glycol 1000 Drugs 0.000 claims description 2
150000001721 carbon Chemical class 0.000 claims 1
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract description 16
230000001225 therapeutic effect Effects 0.000 abstract description 7
239000000186 progesterone Substances 0.000 abstract description 6
229960003387 progesterone Drugs 0.000 abstract description 6
238000010521 absorption reaction Methods 0.000 abstract 1
239000000969 carrier Substances 0.000 abstract 1
230000003152 gestagenic effect Effects 0.000 abstract 1
230000001737 promoting effect Effects 0.000 abstract 1
239000000499 gel Substances 0.000 description 90
239000000243 solution Substances 0.000 description 49
238000009792 diffusion process Methods 0.000 description 38
210000003491 skin Anatomy 0.000 description 27
238000003756 stirring Methods 0.000 description 27
238000009472 formulation Methods 0.000 description 22
238000002360 preparation method Methods 0.000 description 22
RNVYQYLELCKWAN-UHFFFAOYSA-N solketal Chemical compound CC1(C)OCC(CO)O1 RNVYQYLELCKWAN-UHFFFAOYSA-N 0.000 description 22
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 16
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 14
AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 14
229940009662 edetate Drugs 0.000 description 14
229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 14
238000009826 distribution Methods 0.000 description 13
229920000642 polymer Polymers 0.000 description 13
235000010980 cellulose Nutrition 0.000 description 11
230000001186 cumulative effect Effects 0.000 description 11
FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 10
229920003134 Eudragit® polymer Polymers 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 8
210000002615 epidermis Anatomy 0.000 description 8
239000000126 substance Substances 0.000 description 8
230000001476 alcoholic effect Effects 0.000 description 7
230000000694 effects Effects 0.000 description 7
230000004907 flux Effects 0.000 description 7
238000000034 method Methods 0.000 description 7
239000004014 plasticizer Substances 0.000 description 7
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
-1 nomegestrol ester Chemical class 0.000 description 6
238000005063 solubilization Methods 0.000 description 6
230000007928 solubilization Effects 0.000 description 6
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 5
230000009471 action Effects 0.000 description 5
230000002500 effect on skin Effects 0.000 description 5
238000012360 testing method Methods 0.000 description 5
229920003138 Eudragit® L 30 D-55 Polymers 0.000 description 4
229930003427 Vitamin E Natural products 0.000 description 4
238000013019 agitation Methods 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
239000008280 blood Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 description 4
230000036571 hydration Effects 0.000 description 4
238000006703 hydration reaction Methods 0.000 description 4
230000036470 plasma concentration Effects 0.000 description 4
235000019165 vitamin E Nutrition 0.000 description 4
239000011709 vitamin E Substances 0.000 description 4
206010006298 Breast pain Diseases 0.000 description 3
208000006662 Mastodynia Diseases 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000000853 adhesive Substances 0.000 description 3
230000001070 adhesive effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
230000001955 cumulated effect Effects 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
231100000435 percutaneous penetration Toxicity 0.000 description 3
229920000058 polyacrylate Polymers 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
239000008279 sol Substances 0.000 description 3
239000011877 solvent mixture Substances 0.000 description 3
229940088594 vitamin Drugs 0.000 description 3
229930003231 vitamin Natural products 0.000 description 3
235000013343 vitamin Nutrition 0.000 description 3
239000011782 vitamin Substances 0.000 description 3
229940046009 vitamin E Drugs 0.000 description 3
150000003722 vitamin derivatives Chemical class 0.000 description 3
238000005406 washing Methods 0.000 description 3
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 2
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
206010061178 Genital haemorrhage Diseases 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
229920003091 Methocel™ Polymers 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
230000003187 abdominal effect Effects 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
210000004207 dermis Anatomy 0.000 description 2
239000003792 electrolyte Substances 0.000 description 2
210000004696 endometrium Anatomy 0.000 description 2
229960005309 estradiol Drugs 0.000 description 2
229930182833 estradiol Natural products 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
238000002657 hormone replacement therapy Methods 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000009245 menopause Effects 0.000 description 2
239000011707 mineral Substances 0.000 description 2
230000035515 penetration Effects 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
229940068968 polysorbate 80 Drugs 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
229940069328 povidone Drugs 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000008961 swelling Effects 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
238000009736 wetting Methods 0.000 description 2
JHPBZFOKBAGZBL-UHFFFAOYSA-N (3-hydroxy-2,2,4-trimethylpentyl) 2-methylprop-2-enoate Chemical compound CC(C)C(O)C(C)(C)COC(=O)C(C)=C JHPBZFOKBAGZBL-UHFFFAOYSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
SGRCVQDBWHCTIS-UHFFFAOYSA-N 2-nonanoyloxypropyl nonanoate Chemical compound CCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCC SGRCVQDBWHCTIS-UHFFFAOYSA-N 0.000 description 1
QPILHXCDZYWYLQ-UHFFFAOYSA-N 2-nonyl-1,3-dioxolane Chemical compound CCCCCCCCCC1OCCO1 QPILHXCDZYWYLQ-UHFFFAOYSA-N 0.000 description 1
BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
206010001488 Aggression Diseases 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
101100231507 Caenorhabditis elegans ceh-2 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
241000195493 Cryptophyta Species 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
229920003151 Eudragit® RL polymer Polymers 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920000148 Polycarbophil calcium Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
150000008360 acrylonitriles Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
239000008272 agar Substances 0.000 description 1
230000016571 aggressive behavior Effects 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
239000012223 aqueous fraction Substances 0.000 description 1
210000000617 arm Anatomy 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
230000004087 circulation Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
229940124274 edetate disodium Drugs 0.000 description 1
230000002357 endometrial effect Effects 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
238000006266 etherification reaction Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000009501 film coating Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000001879 gelation Methods 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
239000001087 glyceryl triacetate Substances 0.000 description 1
235000013773 glyceryl triacetate Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000036449 good health Effects 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
239000012456 homogeneous solution Substances 0.000 description 1
229920001519 homopolymer Polymers 0.000 description 1
231100000508 hormonal effect Toxicity 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
238000005470 impregnation Methods 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000000938 luteal effect Effects 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
230000004089 microcirculation Effects 0.000 description 1
229940105132 myristate Drugs 0.000 description 1
DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229960001652 norethindrone acetate Drugs 0.000 description 1
229940073665 octyldodecyl myristate Drugs 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
206010033675 panniculitis Diseases 0.000 description 1
238000005192 partition Methods 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000002952 polymeric resin Substances 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
230000001072 progestational effect Effects 0.000 description 1
OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000007873 sieving Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000003068 static effect Effects 0.000 description 1
210000004304 subcutaneous tissue Anatomy 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
235000007586 terpenes Nutrition 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000008719 thickening Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000009466 transformation Effects 0.000 description 1
229960002622 triacetin Drugs 0.000 description 1
LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Oil, Petroleum & Natural Gas (AREA)
Diabetes (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Cosmetics (AREA)

OA1200000259A 1998-03-23 2000-09-22 Composition hormonale topique à effet systémique. OA11489A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9803533A FR2776191B1 (fr)	1998-03-23	1998-03-23	Composition hormonale topique a effet systemique

Publications (1)

Publication Number	Publication Date
OA11489A true OA11489A (fr)	2004-05-08

Family

ID=9524367

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200000259A OA11489A (fr)	1998-03-23	2000-09-22	Composition hormonale topique à effet systémique.

Country Status (28)

Country	Link
US (1)	US20080227763A1 (pl)
EP (1)	EP1066030B1 (pl)
JP (1)	JP4579411B2 (pl)
KR (1)	KR100681322B1 (pl)
CN (1)	CN1161102C (pl)
AP (1)	AP1343A (pl)
AT (1)	ATE353626T1 (pl)
AU (1)	AU754490B2 (pl)
BR (1)	BR9909027A (pl)
CA (1)	CA2324904C (pl)
CY (1)	CY1106463T1 (pl)
CZ (1)	CZ300484B6 (pl)
DE (1)	DE69935135T2 (pl)
DK (1)	DK1066030T3 (pl)
ES (1)	ES2283106T3 (pl)
FR (1)	FR2776191B1 (pl)
HU (1)	HU228863B1 (pl)
ID (1)	ID27988A (pl)
IL (1)	IL138607A0 (pl)
NO (1)	NO331222B1 (pl)
NZ (1)	NZ507201A (pl)
OA (1)	OA11489A (pl)
PL (1)	PL204210B1 (pl)
PT (1)	PT1066030E (pl)
RU (1)	RU2215520C2 (pl)
TR (1)	TR200002751T2 (pl)
WO (1)	WO1999048477A1 (pl)
ZA (1)	ZA200005785B (pl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SK288117B6 (sk) *	1998-11-20	2013-09-03	Skyepharma Canada Inc.	Rapidly dispersing solid dry therapeutic dosage form
WO2001030356A1 (fr) *	1999-10-25	2001-05-03	Laboratoire Theramex	Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
DE10008128A1 (de) *	2000-02-22	2001-08-23	Bayer Ag	Endoparasitizide Mittel
KR100452972B1 (ko) *	2000-05-16	2004-10-14	주식회사 삼양사	경피투여용 하이드로젤 조성물
US7198801B2 (en)	2000-08-03	2007-04-03	Antares Pharma Ipl Ag	Formulations for transdermal or transmucosal application
US8980290B2 (en)	2000-08-03	2015-03-17	Antares Pharma Ipl Ag	Transdermal compositions for anticholinergic agents
CA2418135C (en)	2000-08-03	2011-09-20	Antares Pharma Ipl Ag	Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
FR2814074B1 (fr) *	2000-09-15	2003-03-07	Theramex	Nouvelles compositions estro-progestatives topiques a effet systemique
US7803392B2 (en)	2000-12-27	2010-09-28	University Of Kentucky Research Foundation	pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
US7005557B2 (en) *	2001-07-03	2006-02-28	The Procter & Gamble Company	Film-forming compositions for protecting skin from body fluids and articles made therefrom
GB0119480D0 (en) *	2001-08-09	2001-10-03	Jagotec Ag	Novel compositions
DE10146541A1 (de) *	2001-09-21	2003-04-17	Kade Pharma Fab Gmbh	Arzneimittel auf Basis von Gestagenen zur dermalen Anwendung
CA2538856C (en)	2003-10-10	2010-06-29	Antares Pharma Ipl Ag	Transdermal pharmaceutical formulation for minimizing skin residues
US7425340B2 (en)	2004-05-07	2008-09-16	Antares Pharma Ipl Ag	Permeation enhancing compositions for anticholinergic agents
WO2007124250A2 (en)	2006-04-21	2007-11-01	Antares Pharma Ipl Ag	Methods of treating hot flashes with formulations for transdermal or transmucosal application
WO2006125642A1 (en)	2005-05-27	2006-11-30	Antares Pharma Ipl Ag	Methods and apparatus for transdermal or transmucosal application of testosterone
US7772213B2 (en)	2006-07-27	2010-08-10	Nathan Strick	Composition for the treatment of inflammatory conditions
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
EP2782584B1 (en)	2011-11-23	2021-06-09	TherapeuticsMD, Inc.	Natural combination hormone replacement formulations and therapies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
EP2742932A1 (en) *	2012-12-17	2014-06-18	Laboratorios Ojer Pharma S.L.	Gel compositions
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es)	2014-05-22	2016-10-12	Therapeuticsmd Inc	Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
KR20170040209A (ko)	2014-07-29	2017-04-12	쎄러퓨틱스엠디, 인코퍼레이티드	경피 크림
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
WO2017173044A1 (en)	2016-04-01	2017-10-05	Therapeuticsmd Inc.	Steroid hormone compositions in medium chain oils
KR20180126582A (ko)	2016-04-01	2018-11-27	쎄러퓨틱스엠디, 인코퍼레이티드	스테로이드 호르몬 약제학적 조성물
WO2020161771A1 (ja) *	2019-02-04	2020-08-13	マルホ株式会社	皮膚用組成物
GB2597637A (en) *	2020-06-02	2022-02-09	Surfachem Ltd	Sanitiser composition
US20240315996A1 (en) *	2021-02-02	2024-09-26	DuPont Nutrition USA, Inc.	An aqueous gel composition comprising an ethylcellulose

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1515284A (en) *	1974-05-21	1978-06-21	Gastaud J	Pharmaceutical compositions containing progestogens derived from the 17-alpha-hydroxy-19-nor-progesterone series
ES2180690T3 (es) *	1990-06-01	2003-02-16	Population Council Inc	Preparacion de composiciones que comprenden st1435 para aplicacion topica.
FR2668945B1 (fr) *	1990-11-12	1993-02-19	Theramex	Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
JPH05148146A (ja) *	1991-06-20	1993-06-15	Terumo Corp	水溶性ゲル外用剤
JP2960832B2 (ja) *	1992-05-08	1999-10-12	ペルマテックテクノロジーアクチェンゲゼルシャフト	エストラジオールの投与システム
FR2695826B1 (fr) *	1992-09-21	1995-01-06	Theramex	Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention.
DE4309830C1 (de) *	1993-03-26	1994-05-05	Lohmann Therapie Syst Lts	Wirkstoffpflaster für die Abgabe von Estradiol an die Haut
IL105600A (en) *	1993-05-04	1999-12-31	Allon Blank	Pharmaceutical and cosmetic compositions with increased rate of transdermal penetration and antioxidation protection against degradation containing derivatives of thioglycolic and mercaptopropionic acids some such novel compounds and their use
EP0785211A1 (en) *	1996-01-22	1997-07-23	Laboratoire Theramex	New substituted 19-nor-pregnane derivatives
EP0785212A1 (en) *	1996-01-22	1997-07-23	Laboratoire Theramex	New 19-nor-pregnene derivatives
JP4346696B2 (ja) *	1996-05-28	2009-10-21	久光製薬株式会社	経皮治療用装置
IT1283102B1 (it) *	1996-06-06	1998-04-07	Permatec Nv	Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele

1998
- 1998-03-23 FR FR9803533A patent/FR2776191B1/fr not_active Expired - Fee Related
1999
- 1999-03-23 AU AU28451/99A patent/AU754490B2/en not_active Ceased
- 1999-03-23 ID IDW20002123A patent/ID27988A/id unknown
- 1999-03-23 RU RU2000126490/15A patent/RU2215520C2/ru not_active IP Right Cessation
- 1999-03-23 WO PCT/FR1999/000680 patent/WO1999048477A1/fr not_active Ceased
- 1999-03-23 AT AT99909078T patent/ATE353626T1/de active
- 1999-03-23 PT PT99909078T patent/PT1066030E/pt unknown
- 1999-03-23 NZ NZ507201A patent/NZ507201A/en not_active IP Right Cessation
- 1999-03-23 AP APAP/P/2000/001948A patent/AP1343A/en active
- 1999-03-23 KR KR1020007010569A patent/KR100681322B1/ko not_active Expired - Fee Related
- 1999-03-23 EP EP99909078A patent/EP1066030B1/fr not_active Expired - Lifetime
- 1999-03-23 PL PL343256A patent/PL204210B1/pl unknown
- 1999-03-23 CZ CZ20003471A patent/CZ300484B6/cs not_active IP Right Cessation
- 1999-03-23 ES ES99909078T patent/ES2283106T3/es not_active Expired - Lifetime
- 1999-03-23 TR TR2000/02751T patent/TR200002751T2/xx unknown
- 1999-03-23 DK DK99909078T patent/DK1066030T3/da active
- 1999-03-23 CA CA002324904A patent/CA2324904C/fr not_active Expired - Fee Related
- 1999-03-23 IL IL13860799A patent/IL138607A0/xx unknown
- 1999-03-23 HU HU0101579A patent/HU228863B1/hu not_active IP Right Cessation
- 1999-03-23 DE DE69935135T patent/DE69935135T2/de not_active Expired - Lifetime
- 1999-03-23 JP JP2000537527A patent/JP4579411B2/ja not_active Expired - Fee Related
- 1999-03-23 BR BR9909027-9A patent/BR9909027A/pt not_active IP Right Cessation
- 1999-03-23 CN CNB998064122A patent/CN1161102C/zh not_active Expired - Fee Related
2000
- 2000-09-22 OA OA1200000259A patent/OA11489A/fr unknown
- 2000-09-22 NO NO20004745A patent/NO331222B1/no not_active IP Right Cessation
- 2000-10-18 ZA ZA200005785A patent/ZA200005785B/xx unknown
2007
- 2007-04-26 CY CY20071100563T patent/CY1106463T1/el unknown
2008
- 2008-03-20 US US12/077,665 patent/US20080227763A1/en not_active Abandoned

Also Published As

Publication number	Publication date
FR2776191B1 (fr)	2002-05-31
DK1066030T3 (da)	2007-06-11
NO20004745D0 (no)	2000-09-22
CN1301146A (zh)	2001-06-27
NO20004745L (no)	2000-11-20
ATE353626T1 (de)	2007-03-15
KR20010042152A (ko)	2001-05-25
CY1106463T1 (el)	2012-01-25
CZ300484B6 (cs)	2009-05-27
JP4579411B2 (ja)	2010-11-10
DE69935135T2 (de)	2007-10-31
EP1066030A1 (fr)	2001-01-10
ZA200005785B (en)	2001-06-12
TR200002751T2 (tr)	2000-12-21
CN1161102C (zh)	2004-08-11
RU2215520C2 (ru)	2003-11-10
NZ507201A (en)	2003-07-25
DE69935135D1 (de)	2007-03-29
BR9909027A (pt)	2001-12-11
WO1999048477A1 (fr)	1999-09-30
CA2324904C (fr)	2009-03-03
FR2776191A1 (fr)	1999-09-24
PT1066030E (pt)	2007-05-31
HUP0101579A2 (hu)	2001-11-28
CA2324904A1 (fr)	1999-09-30
JP2002507561A (ja)	2002-03-12
AP1343A (en)	2004-12-15
HU228863B1 (en)	2013-06-28
PL343256A1 (en)	2001-07-30
AU754490B2 (en)	2002-11-21
NO331222B1 (no)	2011-11-07
AP2000001948A0 (en)	2000-12-31
ES2283106T3 (es)	2007-10-16
AU2845199A (en)	1999-10-18
ID27988A (id)	2001-05-03
IL138607A0 (en)	2001-10-31
US20080227763A1 (en)	2008-09-18
CZ20003471A3 (cs)	2001-07-11
EP1066030B1 (fr)	2007-02-14
KR100681322B1 (ko)	2007-02-09
HK1038184A1 (en)	2002-03-08
HUP0101579A3 (en)	2002-01-28
PL204210B1 (pl)	2009-12-31

Publication	Publication Date	Title
CA2324904C (fr)	2009-03-03	Composition hormonale topique a effet systemique
EP1265617B1 (fr)	2006-06-21	Nouvelles compositions estro-progestatives topiques a effet systemique
EP0817621B2 (fr)	2007-12-26	Composition pharmaceutique filmogene pour administration transdermique
EP2391344A1 (en)	2011-12-07	Compositions for nail and skin treatment
EA011244B1 (ru)	2009-02-27	Новые композиции для местной доставки
JP2005519985A (ja)	2005-07-07	医薬組成物
JPS6218526B2 (pl)	1987-04-23
CN117813117A (zh)	2024-04-02	一种芦可替尼组合物及其用途
CN106560175A (zh)	2017-04-12	一种薄荷脑-樟脑低共熔物纳米乳原位凝胶制剂
WO2023051833A1 (zh)	2023-04-06	一种芦可替尼组合物及其制备方法
JP2024505970A (ja)	2024-02-08	エチルセルロースを含有する水性ゲル組成物
JPH0380774B2 (pl)	1991-12-26
MXPA00009299A (en)	2001-09-07	Topical hormonal composition with systemic effect
WO2004054544A1 (fr)	2004-07-01	Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant un progestatif et un oestrogene, son procede de preparation et ses utilisations